Evidence map›Paper›PMID 28886078›Full record

ArticlePloS one2017

MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients.

Xiaomei Wang, Xiaoyu Wen, Jingjing Zhou, Yue Qi, Ruihong Wu, Yao Wang, Yiwen Kui, Rui Hua, Qinglong Jin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Roles of Non-Coding RNAs in Primary Biliary Cholangitis.Frontiers in molecular biosciences · 2022
    Review
  6. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA.International journal of molecular sciences · 2021
    Review
  7. Article
  8. Circulating non-coding RNAs as potential diagnostic biomarkers in liver diseases.Gastroenterology and hepatology from bed to bench · 2021
    Review
  9. Article
  10. Biomarkers for primary biliary cholangitis: current perspectives.Hepatic medicine : evidence and research · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xiaomei WangDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Xiaoyu WenDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Jingjing ZhouDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Yue QiDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Ruihong WuDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Yao WangDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Yiwen KuiDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Rui HuaDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Qinglong JinDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.ORCID http://orcid.org/0000-0002-1286-5103
Jilin University · CNMinistry of Education of the People's Republic of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, there is ample evidence suggesting the important role of microRNAs (miRNAs) in autoimmune diseases via modulating B cells function. Primary biliary cholangitis (PBC) is a progressive immune-mediated liver disease with unclear pathogenic mechanism. Whether the miRNA in peripheral B cells of PBC involve the mechanisms of pathology and progression is not known. The present study explores miRNA deregulation in peripheral B-cell of PBC from stage I to IV and healthy controls. Peripheral B cells were obtained from 72 PBC patients (stage I, n = 17; stage II, n = 23; stage III, n = 16; stage IV, n = 16) and 15 healthy controls. Initially, in a discovery study, miRNA array analysis was performed, subsequently, in a validation study, quantitative PCR was used to investigate miRNA expression profile in B cells of PBS patients compared to healthy controls. Based on bioinformatics analysis, we identified the potential biological processes and significant signaling pathways affected by these microRNAs, and generated the microRNA-gene network. The discovery study identified 558 miRNAs differentially expressed in B cells of PBC patients compared to controls. Interestingly, among all differentially expressed miRNAs, hsa-miR-223-3p and hsa-miR-21-5p were the only miRNAs that showed consistent and significant down-regulation from stage I to stage III of PBC. Bioinformatics showed that potential target genes of both miRNAs involved in migration, cell differentiation, apoptosis, and signal transduction pathways. In conclusion, our results suggest that the expression profiles of miRNA in peripheral B cells of PBC patients are closely associated with the disease progression, especially the down-regulation of hsa-miR-223-3p and hsa-miR-21-5p. Taken together, our study offers novel perspectives on the role of miRNAs in PBC pathogenesis.

Indexed as

BiomarkersB-LymphocytesCase-Control StudiesCholangitisComputational BiologyDisease ProgressionGene Expression ProfilingGene Expression RegulationGene OntologyGene Regulatory NetworksHumansMicroRNAsMiddle AgedReproducibility of ResultsTranscriptomeBiomarkersMicroRNAsMIR223, humanMIRN21 microRNA, human

Identifiers

PMID28886078
PMCPMC5590910
OpenAlexW2753118839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.